EUVIMEDEUVIMED entdecken
Crossref

Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia

Melissa House, James Rowe, Audrey Walters, Chunyan Liu, Shelley R Ehrlich, Thomas Nienaber iD, Erik B Hysinger iD, Paul Kingma iD, Shawn K Ahlfeld

Pediatric Pulmonology · 2025-09 · 60 (9)

DOI: 10.1002/ppul.71275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 09.09.2025. Verfasst von Melissa House und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neonatology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Dexamethasone, Bronchopulmonary Dysplasia, Glucocorticoids, Respiratory Insufficiency. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: The authors received no specific funding for this study..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To wean respiratory support, preterm infants with severe respiratory failure are often administered systemic corticosteroids. We sought to evaluate if postnatal age or clinical characteristics predicted death or tracheostomy following systemic dexamethasone in evolving bronchopulmonary dysplasia. Study Design We performed a retrospective study of infants born at ≤ 30 weeks' gestational age cared for at a Level IV referral center from 2009 to 2019 who received a complete course of systemic dexamethasone beyond 4 weeks of age for the indication of preventing death and/or liberating from positive pressure ventilation. Clinical variables at the initiation of dexamethasone were examined by regression analysis, and receiver operator curves were constructed for their ability to predict death or tracheostomy.

Results

Of the 81 infants that received a complete course of dexamethasone, 52% died or required tracheostomy. At onset of the dexamethasone course, infants ultimately requiring tracheostomy were more likely to be small for gestational age (SGA) ( p = 0.02), receive dexamethasone at a significantly later postmenstrual age ( p < 0.01), require higher respiratory support ( p < 0.01), and have concomitant pulmonary hypertension ( p < 0.01). The combination of SGA, a history of late bacterial sepsis, the need for multiple dexamethasone courses, a diagnosis of pulmonary hypertension, and higher respiratory support at onset of dexamethasone course predicted tracheostomy or death (AUC 0.87).

Conclusion

For infants receiving systemic dexamethasone for severe respiratory failure, a combination of clinical characteristics and magnitude of respiratory support may reliably predict inability to wean from positive pressure ventilation, potentially avoiding ineffective dexamethasone exposure. Further validation is required before clinical use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DexamethasoneBronchopulmonary DysplasiaGlucocorticoidsRespiratory InsufficiencyHumansRetrospective StudiesInfant, NewbornMaleFemaleInfant, PrematureTracheostomyGestational AgeVentilator WeaningPositive-Pressure Respiration

Stichwörter der Autor:innen

bronchopulmonary dysplasiacorticosteroidsprematuritytracheostomy

Substanzen

DexamethasoneGlucocorticoids

Autor:innen und Institutionen

  • Division of Neonatology, Department of Pediatrics, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
  • Perinatal Institute, Division of Neonatology and Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
  • Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.

ORCID-Profile: Thomas Nienaber, Erik B Hysinger, Paul Kingma

Förderung

  • The authors received no specific funding for this study.

Zitieren

APA

House, M., Rowe, J., Walters, A., Liu, C., Ehrlich, S. R., Nienaber, T., Hysinger, E. B., Kingma, P., & Ahlfeld, S. K. (2025). Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia. Pediatric Pulmonology, 60(9). https://doi.org/10.1002/ppul.71275

Vancouver

House M, Rowe J, Walters A, Liu C, Ehrlich SR, Nienaber T, et al. Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia. Pediatric Pulmonology. 2025;60(9). doi:10.1002/ppul.71275

BibTeX
@article{House2025,
  author = {House, Melissa and Rowe, James and Walters, Audrey and Liu, Chunyan and Ehrlich, Shelley R and Nienaber, Thomas and Hysinger, Erik B and Kingma, Paul and Ahlfeld, Shawn K},
  title = {Respiratory Outcomes Following Late Postnatal Dexamethasone Administration in Preterm Infants With Bronchopulmonary Dysplasia},
  journal = {Pediatric Pulmonology},
  year = {2025},
  volume = {60},
  number = {9},
  doi = {10.1002/ppul.71275}
}
Kostenlos starten →